Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Sobi" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Sobi for you to read. Along with our medical data and news we also list Sobi Clinical Trials, which are updated daily. BioPortfolio also has a large database of Sobi Companies for you to search.
AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orphan Biovitrum AB (publ) (Sobi). Sobi will commercialise Synagis in the US and around 130 AstraZeneca employees will transfer to Sobi as part of the transaction.
AZ continues sell-off, SOBI spies US expansion
Anglo-Swedish drugmaker AstraZeneca has sold US right for its Synagis infant respiratory drug to Swedish Orphan Biovitrum (Sobi) for an upfront sum of $1.5 billion. The payment consists of $1 billion in cash and $500 million in Sobi ordinary shares, equivalent to a stake in the Swedish company of 8%.
The company will gain an 8 percent ownership stake in Sobi with the deal's total value reaching $2.3 billion when including deferred and contingency payments
AstraZeneca has jettisoned another non-essential asset with the sale of Synagis (palivizumab), a preventative treatment for infections relating to respiratory syncytial virus (RSV), to Swedish rare disease specialist Sobi in a deal worth $1.5 billion. As part of the agreement, AZ will pay an upfront sum of $1 billion in cash and $500 million in newly issued Sobi shares, with deferred and contingen...
"Immunology now becomes the second leg to Sobi and it helps us to articulate what specialty care is about," the company's CEO said on the deal.
Swedish biopharmaceutical firm Swedish Orphan Biovitrum (Sobi) has signed agreements to acquire the rights to AstraZeneca’s Synagis (palivizumab) medicine in...Read More... The post Sobi to buy US rights to AstraZeneca’s Synagis drug for $1.5bn appeared first on Pharmaceutical Technology.
Synagis, the only approved respiratory syncytial virus prophylaxis for high-risk infants, complements Sobi s expertise in paediatrics and immunology
Rare disease group Swedish Orphan Biovitrum (Sobi) says it has gained NHS England reimbursement for Ravicti for long-term management of urea-cycle disorders (UCDs) in adults and children.
NewsAstraZeneca sells U.S. rights to RSV therapy Synagis to Sobi for $1.5 billion upfront. Contributed Author:
AstraZeneca sells US rights to RSV therapy Synagis to Sobi for $1.5 billion upfront https://www.firstwordpharma.com/node/1603969 $AZN $SOBI
Novimmune SA granted Swedish Orphan Biovitrum AB (Sobi) exclusive global rights to emapalumab, an interferon gamma antagonist...
AstraZeneca has agreed to sell the rights to its drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) for an upfront $1.5 billion in cash and shares, plus certain conditional payments. Synagis treats serious lower respiratory tract infect...
Sobi UK and Ireland has announced the launch of Kineret across the country offering a new treatment option for Adult Onset Stills Disease (AOSD) and Systemic-Onset Juvenile Idiopathic Arthritis (SJIA).
In this blog post, we’ll share some highlights about Rami Levin, and see some of the reasons why he was honored in this year’s PharmaVOICE 100. You can also read his full profile here. Since being named president of Sobi North America in 2014, Rami Levin has built the company into a team of nearly […] The post 2018 PharmaVOICE 100 – Rami Levin, President, North America, Sob...
Swedish Orphan Biovitrum (Sobi™) has agreed to acquire U.S. rights to the marketed drug Synagis® (palivizumab) from AstraZeneca, and receive the pharma giant’s half-share of future U.S. profits and losses for the vaccine candidate MEDI8897, for $1.5 billion in cash and stock, plus potential milestone payments. Both Synagis and MEDI18897 are indicated for preventing serious […] The post ...
Two weeks after reporting a 45 percent growth in revenue for the third quarter, compared to last year, Swedish Orphan Biovitrum AB (Sobi) has snapped up the U.S. rights to AstraZeneca’s respiratory drug, Synagis, a drug used to treat RSV in infants, for $1.5 billion.
Synagis is indicated for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) in highly prone infants and is the only approved The post AstraZeneca to sell Synagis US rights to Sobi for $1.5bn appeared first on Pharmaceutical Business review.
Swedish rare diseases specialist Sobi has reported strong financials and the acquisition of a rare disease candidate on the verge...
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sobi in €387 orphan drug deal with Novimmune . from European Biotechnology – first and foremost in European biotech https://ift.tt/2LxeRSu Cet article #news #biotech Sobi in €387 orphan drug deal with Novimmune est apparu en premier sur Biotech 365.
Switzerland’s Novimmune has filed its rare disease drug emapalumab in Europe, days after it sealed a deal selling rights to Sweden’s Sobi. The biotech, based in Geneva and Basel, has filed for a marketing authorisation for emapalumab as a treatmen...
Sobi, an international biopharmaceutical company dedicated to rare diseases, announced today that Carol Satler, M.D., Ph.D., has joined the company as the Vice President of Medical Affairs in North America. Satler has more than 25 years of experience in the healthcare industry spanning roles in medical affairs, clinical research and clinical pract...